Table 3.

 Clinical manifestations and serum antibodies to carbonic anhydrase IV peptide 4 in patients with definite and probable autoimmune pancreatitis

Clinical factor	Manifestation	Antibodies to CA IV peptide 4		p Value
		Positive (n = 9)	Negative (n = 20)
Age/sex	Age of onset	64.1 (10.1)	62.1 (15.4)	NS
	Male	6/9 (66.7%)	12/20 (60.0%)	NS
Immunological tests	γ-globulin (g/dl)	3.48 (1.34)	1.73 (0.73)	<0.001
	IgG (mg/dl)	4140 (775)	2162 (775)	<0.001
	IgM (mg/dl)	125 (126)	132 (120)	NS
	IgA (mg/dl)	372 (302)	210 (86)	<0.05
	ANA (>1+)	4/9 (44.4%)	10/19 (52.6%)	NS
	Rheumatoid factor	4/9 (44.4%)	3/14 (21.4%)	NS
Pancreatic enlargement*	Diffuse	4/9 (44.4%)	13/20 (65.0%)	NS
	Segmental	4/9 (44.4%)	4/20 (25.0%)	NS
MPD narrowing†	Diffuse	6/9 (66.6%)	7/17 (41.2%)	NS
	Segmental	3/9 (33.3%)	9/17 (52.9%)	NS

ANA, antinuclear antibody; MPD, main pancreatic duct.

*Demonstrated by abdominal ultrasonography and/or computed tomography.

†Demonstrated by endoscopic retrograde pancreatography.